A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of ramucirumab in combination with
docetaxel in participants with Stage IV non-small cell lung cancer who have had disease
progression during or after one prior first-line platinum-based chemotherapy with or without
maintenance therapy for advanced/metastatic disease.